Treats relapsing forms of multiple sclerosis (MS). ANDA 207994, held by Zydus Pharms. Fingolimod Hydrochloride.
As of Nov 16, 2026, ANDA 207994 (Fingolimod Hydrochloride), held by Zydus Pharms, was first approved by FDA on Oct 14, 2020, with 2 approved supplements and 0 published complete response letters.
Fingolimod is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 14, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fingolimod HydrochlorideEQ 0.5MG BASE · capsule;oral | Fingolimod Hydrochloride | Rx |
| Apr 28, 2025 | Supplement 3Labeling · Standard review | Approved | None posted |
| Apr 28, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Oct 14, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters